Zafgen shares plunge as another fatality reported with beloranib

2 December 2015

Shares of Boston, USA-based biotech firm Zafgen (Nasdaq: ZFGN) plunged as much as 57% to $6.95 in pre-market trading this morning, after the company reported that another patient with a very rare disease called Prader-Willi syndrome who took part in a trial of the company's obesity drug candidate beloranib has died due to a blood clot.

In a statement this morning, the company said it had learned the day earlier that a patient receiving beloranib as part of the open label extension (OLE) portion of the Phase III study was diagnosed with bilateral pulmonary emboli and has died.

The company said it is discussing its next steps for development of the drug with the Food and Drug Administration, but added that it continues to expect top-line results of the randomized portion of the ZAF-311 clinical trial in the first quarter of 2016.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK